UC San Diego awarded $80M to expand clinical trials and train future researchers

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0

At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).

FDA issues reminder to sponsors: Disclose clinical trial results

FDA issued a stern reminder to medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials.gov.

Health groups urge Bhattacharya, in his position of acting CDC director, to restore staff in the Office on Smoking and Health

A coalition of public health groups sent a formal letter to NIH Director and Acting CDC Director Jay Bhattacharya April 15 highlighting the need for the immediate restoration of full staffing and resources to the CDC’s Office on Smoking and Health.

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced the appointment of Salwan Al Mutar as director of Clinical Research at START Dallas-Fort Worth.

April 17, 2026

Vol.52 No.15

Clinical Roundup

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

Patients with stage 3 colon cancer with deficient DNA mismatch repair had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq) was added to standard chemotherapy after surgery, according to a study by researchers at the Alliance for Clinical Trials in Oncology.

April 17, 2026

Vol.52 No.15

Clinical Roundup

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Patients with pancreatic cancer who received the experimental drug elraglusib, alongside standard chemotherapy, were twice as likely to be alive after one year of treatment, compared to those receiving chemotherapy alone, according to the results of a randomized phase II clinical trial conducted by researchers at Northwestern University. The drug also reduced the risk of death by 38%.

April 17, 2026

Vol.52 No.15

UC San Diego awarded $80M to expand clinical trials and train future researchers

YOU MAY BE INTERESTED IN

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0

FDA issues reminder to sponsors: Disclose clinical trial results

Health groups urge Bhattacharya, in his position of acting CDC director, to restore staff in the Office on Smoking and Health

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Renew today!

Subscriber content

Never miss an issue!

Login

UC San Diego awarded $80M to expand clinical trials and train future researchers

YOU MAY BE INTERESTED IN

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budgetFox Chase’s Winn contemplates Crossroads 2.0

FDA issues reminder to sponsors: Disclose clinical trial results

Health groups urge Bhattacharya, in his position of acting CDC director, to restore staff in the Office on Smoking and Health

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Never miss an issue!

Login

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0